Sulaiman Al Habib H1 2021 profit up 47% to SAR 644 mln

Dr. Sulaiman Al Habib Medical Group reported a net profit after Zakat and tax of SAR 644 million for the first half of 2021, a 47% increase, compared to SAR 438.9 million in the same period a year ago.

The company attributed the profit rise to 35.3% increase in revenues, driven by the growth in the hospital segment, due to rise in number of patients.

The company also cited 35.97% increase in EBITDA and 46.84% rise in net income for the profit growth.

Financials (M)

Item	6m 2020	6m 2021	Change‬
Revenues	2,546.35	3,446.00	35.3 %
Gross Income	759.71	1,100.44	44.8 %
Operating Income	461.92	689.36	49.2 %
Net Income	438.85	644.40	46.8 %
Average Shares	350.00	350.00	-
EPS (Riyals)	1.25	1.84	46.8 %

The company’s Q2 net profit after Zakat and tax increased by 69% year-on-year (YoY) to SAR 325 million due to 45.57% rise in revenues, higher net income by 69.26%, and 47.58% rise in EBITDA.

On a quarterly basis, Q2 net profit increased 2% due to higher revenue, which was not impacted by the seasonality factors.

Current Quarter Comparison (M)

Compared With The

Item	Q2 2020	Q2 2021	Change‬
Revenues	1,203.01	1,751.21	45.6 %
Gross Income	359.86	551.02	53.1 %
Operating Income	203.31	339.73	67.1 %
Net Income	192.25	325.40	69.3 %
Average Shares	350.00	350.00	-
EPS (Riyals)	0.55	0.93	69.3 %

Item	Q1 2021	Q2 2021	Change‬
Revenues	1,694.79	1,751.21	3.3 %
Gross Income	549.42	551.02	0.3 %
Operating Income	349.63	339.73	(2.8 %)
Net Income	319.00	325.40	2.0 %
Average Shares	350.00	350.00	-
EPS (Riyals)	0.91	0.93	2.0 %

View other reports

Share Price

Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)

	Current
Market Cap (M Riyal)	100,310.00
Enterprise Value (EV) (M)	105,278.80
Shares Outstanding ((M))	350.00
EPS ( Riyal) (TTM)	6.36
Book Value (BV) ( Riyal)	19.97
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	46.25
P/E (TTM)	45.05
Price/book	14.35
Return on Average Assets (%) (TTM)	13.0
Return on Average Equity (%) (TTM)	33.3

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2012	-	-	-	-	-	-
Q2 2012	-	-	-	-	-	-
Q3 2012	-	-	-	-	-	-
Q4 2012	-	-	-	-	-	-
2012	-	-	-	-	-	-
Q1 2013	-	-	-	-	-	-
Q2 2013	-	-	-	-	-	-
Q3 2013	-	-	-	-	-	-
Q4 2013	-	-	-	-	-	-
2013	-	-	-	-	-	-
Q1 2014	-	-	-	-	-	-
Q2 2014	-	-	-	-	-	-
Q3 2014	-	-	-	-	-	-
Q4 2014	-	-	-	-	-	-
2014	-	-	-	-	-	-
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	5,122.63	-	2,215.70	-	1,348.96	-
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	4,868.00	(5.0 %)	1,888.69	(14.8 %)	924.66	(31.5 %)
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	4,379.03	(10.0 %)	1,265.38	(33.0 %)	655.26	(29.1 %)
Q1 2018	1,169.41	-	361.40	-	221.01	-
Q2 2018	1,068.31	-	290.57	-	153.73	-
Q3 2018	1,145.35	-	354.30	-	215.17	-
Q4 2018	1,204.57	-	355.74	-	211.62	-
2018	4,587.63	4.8 %	1,362.01	7.6 %	801.52	22.3 %
Q1 2019	1,227.90	5.0 %	404.20	11.8 %	248.18	12.3 %
Q2 2019	1,157.19	8.3 %	334.70	15.2 %	163.58	6.4 %
Q3 2019	1,226.74	7.1 %	348.97	(1.5 %)	192.48	(10.5 %)
Q4 2019	1,404.45	16.6 %	435.67	22.5 %	263.49	24.5 %
2019	5,016.28	9.3 %	1,523.54	11.9 %	867.72	8.3 %
Q1 2020	1,343.34	9.4 %	399.85	(1.1 %)	258.61	4.2 %
Q2 2020	1,203.01	4.0 %	359.86	7.5 %	203.31	24.3 %
Q3 2020	1,623.91	32.4 %	558.89	60.2 %	323.89	68.3 %
Q4 2020	1,691.35	20.4 %	545.81	25.3 %	329.05	24.9 %
2020	5,861.61	16.9 %	1,864.41	22.4 %	1,114.86	28.5 %
Q1 2021	1,694.79	26.2 %	549.42	37.4 %	349.63	35.2 %
Q2 2021	1,751.21	45.6 %	551.02	53.1 %	339.73	67.1 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2011	-	-	-	-	-	-
2012	-	-	-	-	-	-
2013	-	-	-	-	-	-
2014	-	-	-	-	-	-
2015	5,122.63	-	2,215.70	-	1,348.96	-
2016	4,868.00	(5.0 %)	1,888.69	(14.8 %)	924.66	(31.5 %)
2017	4,379.03	(10.0 %)	1,265.38	(33.0 %)	655.26	(29.1 %)
2018	4,587.63	4.8 %	1,362.01	7.6 %	801.52	22.3 %
2019	5,016.28	9.3 %	1,523.54	11.9 %	867.72	8.3 %
2020	5,861.61	16.9 %	1,864.41	22.4 %	1,114.86	28.5 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2012	-	-	-	-	-	-
Q2 2012	-	-	-	-	-	-
Q3 2012	-	-	-	-	-	-
Q4 2012	-	-	-	-	-	-
2012	-	-	-	-	-	-
Q1 2013	-	-	-	-	-	-
Q2 2013	-	-	-	-	-	-
Q3 2013	-	-	-	-	-	-
Q4 2013	-	-	-	-	-	-
2013	-	-	-	-	-	-
Q1 2014	-	-	-	-	-	-
Q2 2014	-	-	-	-	-	-
Q3 2014	-	-	-	-	-	-
Q4 2014	-	-	-	-	-	-
2014	-	-	-	-	-	-
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	1,328.87	-	3.80	-	1,328.87	3.80
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	1,009.94	(24.0 %)	2.89	-	1,009.94	2.89
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	656.17	(35.0 %)	1.87	-	656.17	1.87
Q1 2018	216.53	-	0.62	-	216.53	0.62
Q2 2018	151.51	-	0.43	-	151.51	0.43
Q3 2018	207.93	-	0.59	-	207.93	0.59
Q4 2018	225.34	-	0.64	-	225.34	0.64
2018	801.31	22.1 %	2.29	-	801.31	2.29
Q1 2019	234.08	8.1 %	0.67	-	234.08	0.67
Q2 2019	167.97	10.9 %	0.48	-	167.97	0.48
Q3 2019	198.00	(4.8 %)	0.57	-	198.00	0.57
Q4 2019	270.18	19.9 %	0.77	-	270.18	0.77
2019	870.23	8.6 %	2.49	-	870.23	2.49
Q1 2020	246.60	5.3 %	0.70	-	246.60	0.70
Q2 2020	192.25	14.5 %	0.55	-	192.25	0.55
Q3 2020	298.80	50.9 %	0.85	-	298.80	0.85
Q4 2020	317.83	17.6 %	0.91	-	317.83	0.91
2020	1,055.48	21.3 %	3.02	-	1,055.48	3.02
Q1 2021	319.00	29.4 %	0.91	-	319.00	0.91
Q2 2021	325.40	69.3 %	0.93	-	325.40	0.93

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2011	-	-	-	-	-	-
2012	-	-	-	-	-	-
2013	-	-	-	-	-	-
2014	-	-	-	-	-	-
2015	1,328.87	-	3.80	-	1,328.87	3.80
2016	1,009.94	(24.0 %)	2.89	-	1,009.94	2.89
2017	656.17	(35.0 %)	1.87	-	656.17	1.87
2018	801.31	22.1 %	2.29	-	801.31	2.29
2019	870.23	8.6 %	2.49	-	870.23	2.49
2020	1,055.48	21.3 %	3.02	-	1,055.48	3.02

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2012	-	-	-
Q2 2012	-	-	-
Q3 2012	-	-	-
Q4 2012	-	-	-
2012	-	-	-
Q1 2013	-	-	-
Q2 2013	-	-	-
Q3 2013	-	-	-
Q4 2013	-	-	-
2013	-	-	-
Q1 2014	-	-	-
Q2 2014	-	-	-
Q3 2014	-	-	-
Q4 2014	-	-	-
2014	-	-	-
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
2015	43.25 %	29.04 %	25.94 %
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
2016	38.80 %	22.35 %	20.75 %
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
2017	28.90 %	19.57 %	14.98 %
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	29.69 %	21.84 %	17.47 %
2018	29.69 %	21.84 %	17.47 %
Q1 2019	30.24 %	22.28 %	17.62 %
Q2 2019	30.60 %	22.42 %	17.64 %
Q3 2019	29.97 %	21.82 %	17.14 %
Q4 2019	30.37 %	22.40 %	17.35 %
2019	30.37 %	22.40 %	17.35 %
Q1 2020	29.60 %	22.52 %	17.20 %
Q2 2020	29.83 %	23.35 %	17.52 %
Q3 2020	31.47 %	24.38 %	18.08 %
Q4 2020	31.81 %	24.44 %	18.01 %
2020	31.81 %	24.44 %	18.01 %
Q1 2021	32.42 %	24.53 %	18.15 %
Q2 2021	32.61 %	24.54 %	18.65 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2011	-	-	-
2012	-	-	-
2013	-	-	-
2014	-	-	-
2015	43.25 %	29.04 %	25.94 %
2016	38.80 %	22.35 %	20.75 %
2017	28.90 %	19.57 %	14.98 %
2018	29.69 %	21.84 %	17.47 %
2019	30.37 %	22.40 %	17.35 %
2020	31.81 %	24.44 %	18.01 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2012	-	-	-
Q2 2012	-	-	-
Q3 2012	-	-	-
Q4 2012	-	-	-
Q1 2013	-	-	-
Q2 2013	-	-	-
Q3 2013	-	-	-
Q4 2013	-	-	-
Q1 2014	-	-	-
Q2 2014	-	-	-
Q3 2014	-	-	-
Q4 2014	-	-	-
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	30.90 %	23.18 %	18.52 %
Q2 2018	27.20 %	19.05 %	14.18 %
Q3 2018	30.93 %	23.14 %	18.15 %
Q4 2018	29.53 %	21.76 %	18.71 %
Q1 2019	32.92 %	24.80 %	19.06 %
Q2 2019	28.92 %	19.88 %	14.52 %
Q3 2019	28.45 %	20.73 %	16.14 %
Q4 2019	31.02 %	23.83 %	19.24 %
Q1 2020	29.77 %	25.06 %	18.36 %
Q2 2020	29.91 %	23.54 %	15.98 %
Q3 2020	34.42 %	24.91 %	18.40 %
Q4 2020	32.27 %	24.14 %	18.79 %
Q1 2021	32.42 %	25.27 %	18.82 %
Q2 2021	31.47 %	23.90 %	18.58 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2012	-	-	-	-
Q2 2012	-	-	-	-
Q3 2012	-	-	-	-
Q4 2012	-	-	-	-
Q1 2013	-	-	-	-
Q2 2013	-	-	-	-
Q3 2013	-	-	-	-
Q4 2013	-	-	-	-
Q1 2014	-	-	-	-
Q2 2014	-	-	-	-
Q3 2014	-	-	-	-
Q4 2014	-	-	-	-
Q1 2015	-	-	-	-
Q2 2015	-	-	-	-
Q3 2015	-	-	-	-
Q4 2015	-	-	-	-
Q1 2016	-	-	-	-
Q2 2016	-	-	-	-
Q3 2016	-	-	-	-
Q4 2016	-	-	-	-
Q1 2017	-	-	-	-
Q2 2017	-	-	-	-
Q3 2017	-	-	-	-
Q4 2017	-	-	-	-
Q1 2018	350.00	-	-	11.82
Q2 2018	350.00	-	-	12.26
Q3 2018	350.00	-	-	12.86
Q4 2018	350.00	2.29	2.29	12.37
Q1 2019	350.00	2.34	2.34	12.43
Q2 2019	350.00	2.39	2.39	11.79
Q3 2019	350.00	2.36	2.36	12.36
Q4 2019	350.00	2.49	2.49	12.55
Q1 2020	350.00	2.52	2.52	13.25
Q2 2020	350.00	2.59	2.59	13.29
Q3 2020	350.00	2.88	2.88	13.74
Q4 2020	350.00	3.02	3.02	14.03
Q1 2021	350.00	3.22	3.22	14.33
Q2 2021	350.00	3.60	3.60	14.56

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2011	-	-	-	-
2012	-	-	-	-
2013	-	-	-	-
2014	-	-	-	-
2015	350.00	3.80	3.80	10.38
2016	350.00	2.89	2.89	12.21
2017	350.00	1.87	1.87	12.34
2018	350.00	2.29	2.29	12.37
2019	350.00	2.49	2.49	12.55
2020	350.00	3.02	3.02	14.03

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2012	-	-	-
Q2 2012	-	-	-
Q3 2012	-	-	-
Q4 2012	-	-	-
Q1 2013	-	-	-
Q2 2013	-	-	-
Q3 2013	-	-	-
Q4 2013	-	-	-
Q1 2014	-	-	-
Q2 2014	-	-	-
Q3 2014	-	-	-
Q4 2014	-	-	-
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	21.77	21.77	4.14
Q2 2020	29.06	29.06	5.67
Q3 2020	33.48	33.48	7.01
Q4 2020	36.14	36.14	7.77
Q1 2021	38.48	38.48	8.65
Q2 2021	45.35	45.35	11.22

Period	P/E	Adjusted P/E	Price/book
2011	-	-	-
2012	-	-	-
2013	-	-	-
2014	-	-	-
2015	-	-	-
2016	-	-	-
2017	-	-	-
2018	-	-	-
2019	-	-	-
2020	36.14	36.14	7.77

Business Segments (Million)

Compared With The

Period	Hospitals	Pharmacies	Others
Q1 2018	970.00	189.00	10.00
Q2 2018	865.00	174.00	30.00
Q3 2018	908.00	175.00	62.00
Q4 2018	938.00	199.00	68.00
Q1 2019	999.00	208.00	21.00
Q2 2019	916.00	201.00	40.00
Q3 2019	984.00	203.00	40.00
Q4 2019	1,102.00	242.00	60.00
Q1 2020	1,053.00	237.00	53.00
Q2 2020	931.00	209.00	63.00
Q3 2020	1,272.00	261.00	91.00
Q4 2020	1,346.00	294.00	52.00
Q1 2021	1,320.00	313.00	62.00
Q2 2021	1,366.00	315.00	70.00

Period	Hospitals	Pharmacies	Others
2015	4,485.00	598.00	40.00
2016	4,157.00	656.00	55.00
2017	3,671.00	680.00	28.00
2018	3,681.00	737.00	170.00
2019	4,001.00	854.00	161.00
2020	4,602.00	1,001.00	259.00

Analysts Estimates (Million)

Item	Q2 2021 (e)	Q2 2021 (a)	Change‬
Average	324.13	325.40	0.39 %

Estimates vs Actual (Million)

Item	Q2 2021 (e)	Q2 2021 (a)	Change
Riyad Capital	324.00	325.40	0.4 %
AlJazira Capital	323.20	325.40	0.7 %
OSOOL AND BAKHEET	334.30	325.40	(2.7) %
SNB Capital	315.00	325.40	3.3 %

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Sulaiman Al Habib H1 2021 profit up 47% to SAR 644 mln

Financials (M)

Current Quarter Comparison (M)

View other reports

Share Price

Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)

Financial Ratios

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2021 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Sulaiman Al Habib H1 2021 profit up 47% to SAR 644 mln

Financials (M)

Current Quarter Comparison (M)

View other reports

Share Price

Dr. Sulaiman Al Habib Medical Services Group (SULAIMAN ALHABIB)

Financial Ratios

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q2 2021

Revenue by Business Segment (Latest) 2021 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Popular Links

Quick Links

About Us

Join Us

Follow Us

Business Segments (Million)